|
|
|
Scientific Literature, colon cancer
-
Abdelrazeq AS, Scott N, Thorn C, Verbeke CS, Ambrose NS, Botterill ID, Jayne DG 2008 The impact of spontaneous tumour perforation on outcome following colon cancer surgery.
Colorectal Dis. Feb 9 [Epub ahead of print].
-
Abir F, Alva S, Kaminski DL, Longo WE 2005 The role of arachidonic acid regulatory enzymes in colorectal disease.
Dis. Colon Rectum 48: 1471-1483.
*
-
Aboian E, Winter DC, Metcalf DR, Wolff BG 2006 Perineal hernia after proctectomy: prevalence, risks, and management.
Dis. Colon Rectum 49: 1564-1568.
*
-
Achiam MP, Chabanova E, Logager VB, Thomsen HS, Nielsen OH 2005 MR colonography: a new diagnostic tool.
Ugeskr. Laeger. 167: 4279-4284.
-
Adachi Y, Itoh F, Yamamoto H, Iku S, Matsuno K, Arimura Y, Imai K 2001 Retinoic acids reduce matrilysin (matrix metalloproteinase 7) and inhibit tumor cell invasion in human colon cancer.
Tumour Biol. 22: 247-253.
-
Adair SJ, Carr TM, Fink MJ, Slingluff CL Jr, Hogan KT 2008 The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
J. Immunother. 31: 7-17.
-
Adams LS, Seeram NP, Aggarwal BB, Takada Y, Sand D, Heber D 2006 Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells.
J. Agric. Food Chem. 54: 980-985.
-
Adler A, Roll S, Marowski B, Drossel R, Rehs HU, Willich SN, Riese J, Wiedenmann B, Rosch T; for the Berlin Private-Practice Gastroenterology Working Group. 2007 Appropriateness of colonoscopy in the era of colorectal cancer screening: a prospective, multicenter study in a private-practice setting (Berlin Colonoscopy Project 1, BECOP 1).
Dis. Colon Rectum 50: 1628-1638.
*
-
Adler M, Demols A, Franchimont D, Van Laethem JL, Van Gossum A 2001 Screening for colorectal cancer by endoscopy: rectosigmoidoscopy or coloscopy?
Rev. Med. Brux. 22: A210-A213.
-
Adolfsson O, Meydani SN, Russell RM 2004 Yogurt and gut function.
Am. J. Clin. Nutr. 80: 245-256.
*
-
Agaba AE, Berry N, Agaba PO, Charaklias N, Wong LS 2006 One stop rectal bleeding clinic: the Coventry experience.
Int. Surg. 91: 288-290.
-
Agarwal B, Swaroop P, Protiva P, Raj SV, Shirin H, Holt PR 2003 Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells.
Apoptosis 8: 649-654.
*
-
Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB 2006 Anticancer potential of silymarin: from bench to bed side.
Anticancer Res. 26: 4457-4498.
-
Aggarwal BB, Sethi G, Nair A, Ichikawa H 2006 Nuclear factor-kB: a holy grail in cancer prevention and therapy.
Current Signal Transduction Therapy 1: 25-52. *
-
Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ 2003 Osteopontin identified as colon cancer tumor progression marker.
C.R. Biol. 326: 1041-1043.
-
Agrawal J, Syngal S 2005 Colon cancer screening strategies.
Curr. Opin. Gastroenterol. 21: 59-63.
-
Aguilera O, Pena C, Garcia JM, Larriba MJ, Ordonez-Moran P, Navarro D, Barbachano A, de Silanes IL, Ballestar E, Fraga MF, Esteller M, Gamallo C, Bonilla F, Gonzalez-Sancho JM, Munoz A 2007 The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells.
Carcinogenesis 28: 1877-1884.
*
-
Agundez JAG, Lozano L, Ladero JM, Sastre J, Cerdan FJ, Diaz-Rubio M, Benitez J 2000 N-Acetyltransferase 2 (NAT2) genotype and colorectal carcinoma: risk variability according to tumour site?
Scand. J. Gastroenterol. 35: 1087-1091.
*
-
Ahmed FE 2006 Gene-gene, gene-environment and multiple interactions in colorectal cancer.
J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev. 24: 1-101.
*
-
Ahmed FE 2005 Molecular markers that predict response to colon cancer therapy.
Expert Rev. Mol. Diagn. 5: 353-375.
-
Ahn D, Crawley S, Hokari R, Kato S, Yang S, Li J, Kim Y 2005 TNF-alpha activates MUC2 transcription via NF-kappaB but inhibits via JNK activation.
Cell. Physiol. Biochem. 15: 29-40.
*
-
Aird RE, Thomson M, Macpherson JS, Thurston DE, Jodrell DI, Guichard SM 2008 ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136.
Pharmacogenomics J. 8: 289-296.
-
Akare S, Jean-Louis S, Chen W, Wood DJ, Powell AA, Martinez JD 2006 Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence.
Int. J. Cancer 119: 2958-2969.
*
-
Akedo I, Ishikawa H, Nakamura T, Kimura K, Takeyama I, Suzuki T, Kameyama M, Sato S, Nakamura T, Matsuzawa Y, Kakizoe T, Otani T 1998 Three cases with familial adenomatous polyposis diagnosed as having malignant lesions in the course of a long-term trial using docosahexanoic acid (DHA)-concentrated fish oil capsules.
Jpn. J. Clin. Oncol. 28: 762-765.
-
Albanopoulos K, Armakolas A, Konstadoulakis MM, Leandros E, Tsiobanou E, Katsaragakis S, Alexiou D, Androulakis G 2000 Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer.
Am. J. Gastroenterol. 95: 1056-1061.
*
-
Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, Lance P; Phoenix and Tucson Gastroenterologist Networks 2005 Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence.
J. Natl. Cancer Inst. 97: 846-853.
*
-
Alessandro R, Seidita G, Flugy AM, Damiani F, Russo A, Corrado C, Colomba P, Gullotti L, Buettner R, Bruno L, Leo GD 2007 Role of S128R polymorphism of E-selectin in colon metastasis formation.
Int. J. Cancer 121: 528-535.
*
-
Alexander CL, Urbanski SJ, Hilsden R, Rabin H, Macnaughton WK, Beck PL 2008 The risk of gastrointestinal malignancies in cystic fibrosis. Case report of a patient with a near obstructing villous adenoma found on colon cancer screening and Barrett's esophagus.
J. Cyst. Fibros. 7: 1-6.
-
Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR 2001 Histopathological identification of colon cancer with microsatellite instability.
Am. J. Pathol. 158: 527-535.
*
-
Alexander RJ, Panja A, Kaplan-Liss E, Mayer L, Raicht RF 1996 Expression of protooncogene-encoded mRNA by colonic epithelial cells in inflammatory bowel disease.
Dig. Dis. Sci. 41: 660-669.
-
Alexander RJ, Panja A, Kaplan-Liss E, Mayer L, Raicht RF 1995 Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in inflammatory bowel disease.
Dig. Dis. Sci. 40: 485-494.
-
Alghazeer R, Gao H, Howell NK 2008 Cytotoxicity of oxidised lipids in cultured colonal human intestinal cancer cells (caco-2 cells).
Toxicol. Lett. 180: 202-211.
-
Ali MM, Vaidya V 2007 Vitamin D and cancer.
J. Cancer Res. Ther. 3: 225-230.
*
-
Alkhoury F, Malo MS, Mozumder M, Mostafa G, Hodin RA 2005 Differential regulation of intestinal alkaline phosphatase gene expression by Cdx1 and Cdx2.
Am. J. Physiol. Gastrointest. Liver Physiol. 289: G285-G290.
*
-
Allez M, Modigliani R 2000 Clinical features of inflammatory bowel disease.
Curr. Opin. Gastroenterol. 16: 329-336.
-
Allgayer H, Dietrich CF 2008 Celiac sprue and malignancies: analysis of risks and prevention strategies.
Med. Klin. (Munich) 103: 561-568.
-
Allgayer H, Kruis W 2003 PPAR-ligands: a clinically important regulatory system with multiple options in the treatment of diabetes mellitus, inflammatory bowel disease and in the chemoprevention of colon cancer?
Z. Gastroenterol. 41: 1035-1038.
-
Allgayer H, Tillmann T, Hombach A, Kruis W, Pohl C 2000 Aminosalicylates and aspirin for colonic cancer: from anti-inflammatory to antineoplastic drugs?
Z. Gastroenterol. 38: 963-970.
-
Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV 2007 Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
J. Natl. Cancer Inst. 99: 1462-1470.
*
-
Allred CD, Talbert DR, Southard RC, Wang X, Kilgore MW 2008 PPARgamma1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells.
J. Nutr. 138: 250-256.
*
-
Altschuler EL 2000 Is JC polyoma virus the cause of ulcerative colitis and multiple sclerosis?
Med. Hypotheses 55: 335-336.
-
Andersen K, Vogt C, Blondin D, Beck A, Heinen W, Aurich V, Haussinger D, Modder U, Cohnen M 2006 Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy.
Eur. J. Radiol. 58: 140-146.
-
Anderson DW 2001 Cytokines as drug targets.
IDrugs 4: 375-377.
-
Anderson JC, Gonzalez JD, Messina CR, Pollack BJ 2000 Factors that predict incomplete colonoscopy: thinner is not always better.
Am. J. Gastroenterol. 95: 2784-2787.
*
-
Ando T, Takahashi H, Watanabe O, Maeda O, Ishiguro K, Ishikawa D, Hasegawa M, Ohmiya N, Niwa Y, Goto H 2007 Magnifying chromoscopy, a novel and useful technique for colonoscopy in ulcerative colitis.
World J. Gastroenterol. 13: 2523-2528.
*
-
Andoh A, Tsujikawa T, Fujiyama Y 2003 Role of dietary fiber and short-chain fatty acids in the colon.
Curr. Pharm. Des. 9: 347-358.
-
Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A 2004 Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
N. Engl. J. Med. 350: 2343-2351.
*
-
Andre T, Louvet C, de Gramont A 2004 Colon cancer: what is new in 2004?
Bull. Cancer 91: 75-80.
-
Andrieu N, Launoy G, Guillois R, Ory-Paoletti C, Gignoux M 2004 Estimation of the familial relative risk of cancer by site from a French population based family study on colorectal cancer (CCREF study).
Gut 53: 1322-1328.
*
-
Angelo LS, Kurzrock R 2007 Vascular endothelial growth factor and its relationship to inflammatory mediators.
Clin. Cancer Res. 13: 2825-2830.
*
-
Angulo P 2002 Use of ursodeoxycholic acid in patients with liver disease.
Curr. Gastroenterol. Rep. 4: 37-44.
-
Aparicio-Pages MN, Verspaget HW, Pena AS, Weterman IT, Mieremet-Ooms MA, van der Zon JM, de Bruin PA, Lamers CB 1988 Natural, lectin- and phorbol ester-induced cellular cytotoxicity in Crohn's disease and ulcerative colitis.
J. Clin. Lab. Immunol. 27: 109-113.
-
Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F 2008 Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations.
Cancer Immunol. Immunother. 57: 1727-1733.
-
Arber N, DuBois RN 1999 Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer.
Curr. Gastroenterol. Rep. 1: 441-448.
-
Argov S, Sahu RK, Bernshtain E, Salman A, Shohat G, Zelig U, Mordechai S 2004 Inflamatory bowel diseases as an intermediate stage between normal and cancer: a FTIR-microspectroscopy approach.
Biopolymers 75: 384-392.
*
-
Armenakas NA, Pareek G, Fracchia JA 2004 Iatrogenic bladder perforations: longterm followup of 65 patients.
J. Am. Coll. Surg. 198: 78-82.
*
-
Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A 2001 Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study.
Lancet 357: 262-266.
*
-
Aspinall RJ 2004 Are adherent Escherichia coli in Crohn's disease and colon cancer truly pathogenic?
Gastroenterology 127: 1649-1650.
*
-
Assem ES, Peh KH, Wan BY, Middleton BJ, Dines J, Marson CM 2008 Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction.
Int. Immunopharmacol. Sep 18 [Epub ahead of print].
-
Assi K, Mills J, Owen D, Ong C, St Arnaud R, Dedhar S, Salh B 2008 Integrin-linked kinase regulates cell proliferation and tumor growth in murine colitis-associated carcinogenesis.
Gut 57: 931-940.
-
Assisi A, Banzi R, Buonocore C, Capasso F, Muzio VD, Michelacci F, Renzo D, Tafuri G, Trotta F, Vitocolonna M, Garattini S 2006 Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders.
Int. Clin. Psychopharmacol. 21: 319-336.
-
Atalay G, Cardoso F, Paesmans M, Goldberg RM, Bleiberg H 2003 Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?
Anticancer Drugs 14: 703-713.
-
Atreya R, Neurath MF 2005 Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer.
Clin. Rev. Allergy Immunol. 28: 187-196.
-
Atreya R, Neurath MF 2008 Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer.
Curr. Drug Targets 9: 369-374.
-
Attene-Ramos MS, Wagner ED, Gaskins HR, Plewa MJ 2007 Hydrogen sulfide induces direct radical-associated DNA damage.
Mol. Cancer Res. 5: 455-459.
*
-
Attene-Ramos MS, Wagner ED, Plewa MJ, Gaskins HR 2006 Evidence that hydrogen sulfide is a genotoxic agent.
Mol. Cancer Res. 4: 9-14.
*
-
Aung CS, Faddy HM, Lister EJ, Monteith GR, Roberts-Thomson SJ 2006 Isoform specific changes in PPARalpha and beta in colon and breast cancer with differentiation.
Biochem. Biophys. Res. Commun. 340: 656-660.
*
-
Auslander JN, Lieberman DA, Sonnenberg A 2005 Lack of seasonal variation in the endoscopic diagnoses of Crohn's disease and ulcerative colitis.
Am. J. Gastroenterol. 100: 2233-2238.
*
-
Auwerx J 2002 Nuclear receptors. I. PPAR gamma in the gastrointestinal tract: gain or pain?
Am. J. Physiol. Gastrointest. Liver Physiol. 282: G581-G585.
*
-
Azria D, Larbouret C, Garambois V, Gourgou S, Martineau P, Robert B, Dubois JB, Pelegrin A 2004 A bispecific antibody to enhance radiotherapy by tumor necrosis factor-alpha in human CEA-expressing digestive tumors.
Int. J. Radiat. Oncol. Biol. Phys. 58: 580-588.
-
Bachwich DR, Lichtenstein GR, Traber PG 1994 Cancer in inflammatory bowel disease.
Med. Clin. North Am. 78: 1399-1412.
-
Backlund MG, Mann JR, Dubois RN 2005 Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2.
Oncology 69: 28S-32S.
-
Badn W, Kalliomaki S, Widegren B, Sjogren HO 2006 Low-dose combretastatin a4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma.
Clin. Cancer Res. 12: 4714-4719.
*
-
Badoual C, Bouchaud G, Agueznay Nel H, Mortier E, Hans S, Gey A, Fernani F, Peyrard S, Puig PL, Bruneval P, Sastre X, Plet A, Garrigue-Antar L, Quintin-Colonna F, Fridman WH, Brasnu D, Jacques Y, Tartour E 2008 The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer.
Cancer Res. 68: 3907-3914.
*
-
Bae SJ, Kim JW, Kang H, Hwang SG, Oh D, Kim NK 2008 Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C>T) gene and colon cancer in Korea.
Anticancer Res. 28: 1271-1276.
-
Baert FJ, Rutgeerts PJ 2000 Medical therapies for ulcerative colitis and Crohn's disease.
Curr. Gastroenterol. Rep. 2: 446-450.
-
Bagnoli S, Putignano AL, Melean G, Baglioni S, Sestini R, Milla M, d'Albasio G, Genuardi M, Pacini F, Trallori G, Papi L 2004 Susceptibility to refractory ulcerative colitis is associated with polymorphism in the hMLH1 mismatch repair gene.
Inflamm. Bowel Dis. 10: 705-708.
*
-
Bai L, Kao JY, Law DJ, Merchant JL 2006 Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection.
Gastroenterology 131: 841-852.
*
-
Baijal PK, Fitzpatrick DW, Bird RP 1998 Modulation of colonic xenobiotic metabolizing enzymes by feeding bile acids: comparative effects of cholic, deoxycholic, lithocholic and ursodeoxycholic acids.
Food Chem. Toxicol. 36: 601-607.
*
-
Baisse B, Fontolliet C, Bian YS, Vuilleumier H, Benhattar J 2004 Synchronous ileal and colonic adenocarcinomas associated with Crohn's disease: report of a case with a focus on genetic alterations and carcinogenesis.
J. Clin. Pathol. 57: 885-887.
*
-
Balleste B, Bessa X, Pinol V, Castellvi-Bel S, Castells A, Alenda C, Paya A, Jover R, Xicola RM, Pons E, Llor X, Cordero C, Fernandez-Banares F, de Castro L, Rene JM, Andreu M 2007 Detection of metachronous neoplasms in colorectal cancer patients: identification of risk factors.
Dis. Colon Rectum 50: 971-980.
*
-
Ballestero MR, Monte MJ, Briz O, Jimenez F, Gonzalez-San Martin F, Marin JJ 2006 Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps.
Biochem. Pharmacol. 72: 729-738.
*
-
Ban JO, Hwang IG, Kim TM, Hwang BY, Lee US, Jeong HS, Yoon YW, Kimz DJ, Hong JT 2007 Anti-proliferate and pro-apoptotic effects of 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyranone through inactivation of NF-kappaB in human colon cancer cells.
Arch. Pharm. Res. 30: 1455-1463.
-
Bansal P, Sonnenberg A 1996 Risk factors of colorectal cancer in inflammatory bowel disease.
Am. J. Gastroenterol. 91: 44-48.
-
Barchana M, Liphshitz I, Rozen P 2004 Trends in colorectal cancer incidence and mortality in the Israeli Jewish ethnic populations.
Fam. Cancer 3: 207-214.
*
-
Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H 2007 Identification of stem cells in small intestine and colon by marker gene Lgr5.
Nature 449: 1003-1007.
*
-
Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Porteous ME, Campbell H, Dunlop MG 2006 Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer.
N. Engl. J. Med. 354: 2751-2763.
*
-
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L et al 2003 A randomized trial of aspirin to prevent colorectal adenomas.
N. Engl. J. Med. 348: 891-899.
*
-
Barreda B F, Combe G J, Valdez P LA, Sanchez L J 2007 Clinical aspects in polyps of the colon.
Rev. Gastroenterol. Peru 27: 131-147.
-
Barresi V, Grosso M, Vitarelli E, Tuccari G, Barresi G 2007 5-Lipoxygenase is coexpressed with Cox-2 in sporadic colorectal cancer: a correlation with advanced stage.
Dis. Colon Rectum 50: 1576-1584.
*
-
Bartolini G, Orlandi M, Papi A, Ammar K, Guerra F, Ferreri AM, Rocchi P 2006 A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells.
In Vivo 20: 729-733.
-
Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ 2005 Proprotein convertases: "master switches" in the regulation of tumor growth and progression.
Mol. Carcinog. 44: 151-161.
*
-
Bat B, Lodowska J, Orchel A, Parfiniewicz B, Weglarz L, Dzierzewicz Z, Wilczok T 2004 Evaluation of biotransformation of sulphasalazine in the colon epithelial Caco-2 cells.
Acta Pol. Pharm. 61 Suppl.: 8-10.
-
Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA 2005 Increased risk of rectal cancer after prostate radiation: a population-based study.
Gastroenterology 128: 819-824.
*
-
Beatty PL, Plevy SE, Sepulveda AR, Finn OJ 2007 Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer.
J. Immunol. 179: 735-739.
*
-
Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF 2004 TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling.
Immunity 21: 491-501.
*
-
Becker C, Fantini MC, Wirtz S, Nikolaev A, Kiesslich R, Lehr HA, Galle PR, Neurath MF 2005 In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy.
Gut 54: 950-954.
*
-
Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S, Neurath MF 2005 IL-6 signaling promotes tumor growth in colorectal cancer.
Cell Cycle 4: 217-220.
*
-
Begleiter A, Hewitt D, Maksymiuk AW, Ross DA, Bird RP 2006 A NAD(P)H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancer.
Cancer Epidemiol. Biomarkers Prev. 15: 2422-2426.
*
-
Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI 1995 Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
J. Natl. Cancer Inst. 87: 1593-1602.
-
Belizon A, Sardinha CT, Sher ME 2006 Converted laparoscopic colectomy: what are the consequences?
Surg. Endosc. 20: 947-951.
*
-
Benamouzig R, Chaussade S 2002 Chemoprevention of colorectal cancer.
Presse. Med. 31: 124-127.
-
Beno I, Klvanova J, Magalova T, Brtkova A 2000 Blood levels of natural antioxidants in gastric and colorectal precancerous lesions and cancers in Slovakia.
Neoplasma 47: 37-40.
-
Berger BM, Schroy PC 3rd, Rosenberg JL, Lai-Goldman M, Eisenberg M, Brown T, Rochelle RB, Billings PR 2006 Colorectal cancer screening using stool DNA analysis in clinical practice: early clinical experience with respect to patient acceptance and colonoscopic follow-up of abnormal tests.
Clin. Colorectal Cancer 5: 338-343.
-
Bergmann MM, Jacobs EJ, Hoffmann K, Boeing H 2004 Agreement of self-reported medical history: comparison of an in-person interview with a self-administered questionnaire.
Eur. J. Epidemiol. 19: 411-416.
-
Bergonzelli GE, Blum S, Brussow H, Corthesy-Theulaz I 2005 Probiotics as a treatment strategy for gastrointestinal diseases?
Digestion 72: 57-68.
-
Bergqvist D 2006 Venous thromboembolism: a review of risk and prevention in colorectal surgery patients.
Dis. Colon Rectum 49: 1620-1628.
*
-
Berndt U, Philipsen L, Bartsch S, Wiedenmann B, Baumgart DC, Hammerle M, Sturm A 2008 Systematic high-content proteomic analysis reveals substantial immunologic changes in colorectal cancer.
Cancer Res. 68: 880-888.
*
-
Bernstein CN 1998 Challenges in designing a randomized trial of surveillance colonoscopy in IBD.
Inflamm. Bowel Dis. 4: 132-141.
*
-
Bernstein CN, Blanchard JF, Kliewer E, Wajda A 2001 Cancer risk in patients with inflammatory bowel disease: a population-based study.
Cancer 91: 854-862.
*
-
Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon PH 2002 Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid.
Inflamm. Bowel Dis. 8: 356-361.
*
-
Bernstein CN, Nabalamba A 2007 Hospitalization-based major comorbidity of inflammatory bowel disease in Canada.
Can. J. Gastroenterol. 21: 507-511.
-
Bernstein CN, Shanahan F, Weinstein WM 1994 Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?
Lancet 343: 71-74.
-
Bernstein H, Payne CM, Kunke K, Crowley-Weber CL, Waltmire CN, Dvorakova K, Holubec H, Bernstein C, Vaillancourt RR, Raynes DA, Guerriero V, Garewal H 2004 A proteomic study of resistance to deoxycholate-induced apoptosis.
Carcinogenesis 25: 681-692.
*
-
Berquin IM, Edwards IJ, Chen YQ 2008 Multi-targeted therapy of cancer by omega-3 fatty acids.
Cancer Lett. May 12 [Epub ahead of print].
*
-
Berr F 2004 Photodynamic therapy for cholangiocarcinoma.
Semin. Liver Dis. 24: 177-187.
-
Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C, Charafe-Jauffret E, Loriod B, Bachelart L, Montfort J, Victorero G, Viret F, Ollendorff V, Fert V, Giovaninni M, Delpero JR, Nguyen C, Viens P, Monges G, Birnbaum D, Houlgatte R 2004 Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters.
Oncogene 23: 1377-1391.
*
-
Bhutani MS 2007 Recent developments in the role of endoscopic ultrasonography in diseases of the colon and rectum.
Curr. Opin. Gastroenterol. 23: 67-73.
-
Bi L, Triadafilopoulos G 2003 Exercise and gastrointestinal function and disease: an evidence-based review of risks and benefits.
Clin. Gastroenterol. Hepatol. 1: 345-355.
*
-
Biancone L, Calabrese E, Palmieri G, Petruzziello C, Onali S, Sica GS, Cossignani M, Condino G, Das KM, Pallone F 2008 Ileal lesions in patients with ulcerative colitis after ileo-rectal anastomosis: relationship with colonic metaplasia.
World J. Gastroenterol. 14: 5290-5300.
*
-
Biasco G, Brandi G, Paganelli GM, Rossini FP, Santucci R, Di Febo G, Miglioli M, Risio M, Morselli Labate AM, Barbara L 1995 Colorectal cancer in patients with ulcerative colitis. A prospective cohort study in Italy.
Cancer 75: 2045-2050.
-
Biasco G, Di Marco MC 2005 Folate and prevention of colorectal cancer in ulcerative colitis.
Eur. J Cancer Prev. 14: 395-398.
-
Biasco G, Zannoni U, Paganelli GM, Santucci R, Gionchetti P, Rivolta G, Miniero R, Pironi L, Calabrese C, Di Febo G, Miglioli M 1997 Folic acid supplementation and cell kinetics of rectal mucosa in patients with ulcerative colitis.
Cancer Epidemiol. Biomarkers Prev. 6: 469-471.
-
Bickler SW, Demaio A 2008 Western diseases: current concepts and implications for pediatric surgery research and practice.
Pediatr. Surg. Int. 24: 251-255.
-
Bingham S 2006 The fibre-folate debate in colo-rectal cancer.
Proc. Nutr. Soc. 65: 19-23.
*
-
Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C, Finke J, Peter HH, van Laar J, Breedveld FC, Fibbe WE, Farge D, Gluckman E, Locatelli F, Martini A, van den Hoogen F, van de Putte L, Schattenberg AV, Arnold R, Bacon PA, Emery P, et al 2001 Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.
Ann. Rheum. Dis. 60: 577-584.
*
-
Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S, Laiho P, Aaltonen LA, Orntoft TF 2005 Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid.
Gut 54: 374-384.
*
-
Bises G, Bajna E, Manhardt T, Gerdenitsch W, Kallay E, Cross HS 2007 Gender-specific modulation of markers for premalignancy by nutritional soy and calcium in the mouse colon.
J. Nutr. 137: 211S-2115S.
*
-
Bister VO, Salmela MT, Karjalainen-Lindsberg ML, Uria J, Lohi J, Puolakkainen P, Lopez-Otin C, Saarialho-Kere U 2004 Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer.
Dig. Dis. Sci. 49: 653-661.
*
-
Bjursten M, Bland PW, Willen R, Hornquist EH 2005 Long-term treatment with anti-alpha4 integrin antibodies aggravates colitis in Galphai2-deficient mice.
Eur. J. Immunol. 35: 2274-2283.
*
-
Bleday R, Lee E, Jessurun J, Heine J, Wong WD 1993 Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease.
Dis. Colon Rectum 36: 908-912.
-
Bleiker EM, Menko FH, Taal BG, Kluijt I, Wever LD, Gerritsma MA, Vasen HF, Aaronson NK 2005 Screening behavior of individuals at high risk for colorectal cancer.
Gastroenterology 128: 280-287.
*
-
Bliss CM Jr, Schroy PC 3rd 2004 Endoscopic diagnosis and management of hereditary nonpolyposis colorectal cancer.
Curr. Opin. Gastroenterol. 20: 468-473.
-
Blonski W, Kundu R, Lewis J, Aberra F, Osterman M, Lichtenstein GR 2008 Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis?
Scand. J. Gastroenterol. 43: 698-703.
*
-
Bode MK, Karttunen TJ, Makela J, Risteli L, Risteli J 2000 Type I and III collagens in human colon cancer and diverticulosis.
Scand. J. Gastroenterol. 35: 747-752.
*
-
Boitier E, Gautier JC, Roberts R 2003 Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease.
Comp. Hepatol. 2: 3.
*
-
Bond JH 2005 Progress in refining virtual colonoscopy for colorectal cancer screening.
Gastroenterology 129: 2103-2106.
*
-
Bond JH 2006 The case for direct colonoscopy screening for colorectal cancer.
Am. J. Gastroenterol. 101: 263-265.
*
-
Borchers R, Heinzlmann M, Zahn R, Witter K, Martin K, Loeschke K, Folwaczny C 2002 K-ras mutations in sera of patients with colorectal neoplasias and long-standing inflammatory bowel disease.
Scand. J. Gastroenterol. 37: 715-718.
*
-
Bostick RM, Potter JD, Kushi LH, Sellers TA, Steinmetz KA, McKenzie DR, Gapstur SM, Folsom AR 1994 Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States).
Cancer Causes Control. 5: 38-52.
-
Botoman VA, Bonner GF, Botoman DA 1998 Management of inflammatory bowel disease.
Am. Fam. Physician 57: 57-68, 71-72.
-
Bougnoux P, Menanteau J 2005 Dietary fatty acids and experimental carcinogenesis.
Bull. Cancer 92: 685-696.
-
Bourriaud C, Robins RJ, Martin L, Kozlowski F, Tenailleau E, Cherbut C, Michel C 2005 Lactate is mainly fermented to butyrate by human intestinal microfloras but inter-individual variation is evident.
J. Appl. Microbiol. 99: 201-212.
*
-
Bowles CJ, Leicester R, Romaya C, Swarbrick E, Williams CB, Epstein O 2004 A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow?
Gut 53: 277-283.
*
-
Bozzo F, Bocca C, Colombatto S, Miglietta A 2007 Antiproliferative effect of conjugated linoleic acid in caco-2 cells: involvement of PPARgamma and APC/beta-catenin pathways.
Chem. Biol. Interact. 169: 110-121.
*
-
Branco BC, Sachar DB, Heimann T, Sarpel U, Harpaz N, Greenstein AJ 2008 Adenocarcinoma complicating restorative proctocolectomy for ulcerative colitis with mucosectomy performed by Cavitron Ultrasonic Surgical Aspirator(R).
Colorectal Dis. Jul 25 [Epub ahead of print].
*
-
Brand R 2001 The potential chemoprotective effect of ursodiol.
Am. J. Gastroenterol. 96: 1687. *
-
Brand S, Stepp H, Ochsenkuhn T, Baumgartner R, Baretton G, Holl J, von Ritter C, Paumgartner G, Sackmann M, Paumgartner G 1999 Detection of colonic dysplasia by light-induced fluorescence endoscopy: a pilot study.
Int. J. Colorectal Dis. 14: 63-68.
*
-
Brandlein S, Pohle T, Vollmers C, Wozniak E, Ruoff N, Muller-Hermelink HK, Vollmers HP 2004 CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1.
Oncol. Rep. 11: 777-784.
-
Brannigan AE, Watson RW, Beddy D, Hurley H, Fitzpatrick JM, O'Connell PR 2002 Increased adhesion molecule expression in serosal fibroblasts isolated from patients with inflammatory bowel disease is secondary to inflammation.
Ann. Surg. 235: 507-511.
*
-
Brazowski E, Rozen P, Misonzhnick-Bedny F, Gitstein G 2005 Characteristics of familial juvenile polyps expressing cyclooxygenase-2.
Am. J. Gastroenterol. 100: 130-138.
*
-
Breinholt V, Lauridsen ST, Daneshvar B, Jakobsen J 2000 Dose-response effects of lycopene on selected drug-metabolizing and antioxidant enzymes in the rat.
Cancer Lett. 154: 201-210.
*
-
Brenner DA 2004 Gastrointestinal basic science 2002-2003: the year in review.
Clin. Gastroenterol. Hepatol. 2: 9-13.
*
-
Brenner H, Chang-Claude J, Seiler CM, Sturmer T, Hoffmeister M 2006 Does a negative screening colonoscopy ever need to be repeated?
Gut 55: 1145-1150.
*
-
Brenner H, Chang-Claude J, Seiler CM, Stürmer T, Hoffmeister M 2007 Case-control study supports extension of surveillance interval after colonoscopic polypectomy to at least 5 yr.
Am. J. Gastroenterol. 102: 1739-1744.
-
Brentnall T 2003 UC for UC: ursodiol chemoprevention for ulcerative colitis.
Inflamm. Bowel Dis. 9: 338.
*
-
Brentnall TA 2003 Molecular underpinnings of cancer in ulcerative colitis.
Curr. Opin. Gastroenterol. 19: 64-68.
-
Brentnall TA 2003 Ursodiol: good drug makes good.
Gastroenterology 124: 1139-1140.
*
-
Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, Kowdley KV, Stevens AC, Crispin DA, Emond M, Rubin CE 1996 Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis.
Gastroenterology 110: 331-338.
*
-
Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L 2007 Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis.
Gastroenterology 132: 96-102.
*
-
Bressler B, Paszat LF, Vinden C, Li C, He J, Rabeneck L 2004 Colonoscopic miss rates for right-sided colon cancer: a population-based analysis.
Gastroenterology 127: 452-456.
*
-
Bronowski C, Smith SL, Yokota K, Corkill JE, Martin HM, Campbell BJ, Rhodes JM, Hart CA, Winstanley C 2008 A subset of mucosa-associated Escherichia coli isolates from patients with colon cancer, but not Crohn's disease, share pathogenicity islands with urinary pathogenic E. coli.
Microbiology 154: 571-583.
*
-
Brookes MJ, Hughes S, Turner FE, Reynolds G, Sharma N, Ismail T, Berx G, McKie AT, Hotchin N, Anderson GJ, Iqbal T, Tselepis C 2006 A modulation of iron transport proteins in human colorectal carcinogenesis.
Gut 55: 1449-1460.
*
-
Broom OJ, Massoumi R, Sjolander A 2006 alpha2beta1 integrin signalling enhances cyclooxygenase-2 expression in intestinal epithelial cells.
J. Cell. Physiol. 209: 950-958.
*
-
Broome U 2005 Clinical concepts in PSC.
Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 76. *
-
Broome U, Bergquist A 2006 Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer.
Semin. Liver Dis. 26: 31-41.
*
-
Broome U, Bergquist A 2003 Hepatocellular carcinoma, cholangiocarcinoma, colon and pancreas carcinoma in patients with primary sclerosing cholangitis. Epidemiology and risk factors.
Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 89-90. October 15-16. *
-
Brown S, Baraza W, Hurlstone P 2007 Chromoscopy versus conventional endoscopy for the detection of polyps in the colon and rectum.
Cochrane Database Syst. Rev. 4: CD006439.
-
Bruce WR, Cirocco M, Giacca A, Kim YI, Marcon N, Minkin S 2005 A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, insulin resistance and colonic inflammation.
Br. J. Cancer 93: 639-646.
-
Bruewer M, Krieglstein CF, Utech M, Bode M, Rijcken E, Anthoni C, Laukoetter MG, Schuermann G, Senninger N 2003 Is colonoscopy alone sufficient to screen for ulcerative colitis-associated colorectal carcinoma?
World J. Surg. 27: 611-615.
*
-
Bruining DH, Loftus EV Jr 2008 Crohn's disease clinical issues and treatment: what the radiologist needs to know and what the gastroenterologist wants to know.
Abdom. Imaging May 21 [Epub ahead of print].
*
-
Bruno ME, West RB, Schneeman TA, Bresnick EH, Kaetzel CS 2004 Upstream stimulatory factor but not c-Myc enhances transcription of the human polymeric immunoglobulin receptor gene.
Mol. Immunol. 40: 695-708.
*
-
Bruwer M, Schmid KW, Senninger N, Schurmann G 2002 Immunohistochemical expression of P53 and oncogenes in ulcerative colitis-associated colorectal carcinoma.
World J. Surg. 26: 390-396.
*
-
Buckowitz A, Knaebel HP, Benner A, Blaker H, Gebert J, Kienle P, von Knebel Doeberitz M, Kloor M 2005 Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases.
Br. J. Cancer 92: 1746-1753.
-
Bull AW 2003 The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease.
Arch. Pathol. Lab. Med. 127: 1121-1123.
*
-
Buning C, Schmidt HH, Molnar T, DE Jong DJ, Fiedler T, Buhner S, Sturm A, Baumgart DC, Nagy F, Lonovics J, Drenth JP, Landt O, Nickel R, Buttner J, Lochs H, Witt H 2007 Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis.
Aliment. Pharmacol. Ther. 26: 1025-1033.
*
-
Burke A, Lichtenstein GR, Rombeau JL 1997 Nutrition and ulcerative colitis.
Baillieres Clin. Gastroenterol. 11: 153-174.
-
Burke CA, Bauer WM, Lashner B 2003 Chemoprevention of colorectal cancer: slow, steady progress.
Cleve. Clin. J. Med. 70: 346-350.
*
-
Burmer GC, Crispin DA, Kolli VR, Haggitt RC, Kulander BG, Rubin CE, Rabinovitch PS 1991 Frequent loss of a p53 allele in carcinomas and their precursors in ulcerative colitis.
Cancer Commun. 3: 167-172.
-
Burnand B, Harris JK, Wietlisbach V, Froehlich F, Vader JP, Gonvers JJ, The Epage Study Group 2006 Use, appropriateness, and diagnostic yield of screening colonoscopy: an international observational study (EPAGE).
Gastrointest. Endosc. 63: 1018-1026.
-
Burstein E, Fearon ER 2008 Colitis and cancer: a tale of inflammatory cells and their cytokines.
J. Clin. Invest. 118: 464-467.
*
-
Burt R, Neklason DW 2005 Genetic testing for inherited colon cancer.
Gastroenterology 128: 1696-1716.
*
-
Burt RW 2000 Colon cancer screening.
Gastroenterology 119: 837-853.
*
-
Burt RW, Bishop DT, Cannon-Albright L, Samowitz WS, Lee RL, DiSario JA, Skolnick MH 1992 Population genetics of colonic cancer.
Cancer 70: 1719-1722.
-
Burt RW, Leppert MF, Slattery ML, Samowitz WS, Spirio LN, Kerber RA, Kuwada SK, Neklason DW, Disario JA, Lyon E, Hughes JP, Chey WY, White RL 2004 Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis.
Gastroenterology 127: 444-451.
*
-
Burum-Auensen E, De Angelis PM, Schjolberg AR, Roislien J, Andersen SN, Clausen OP 2007 Spindle proteins Aurora A and BUB1B, but not Mad2, are aberrantly expressed in dysplastic mucosa of patients with longstanding ulcerative colitis.
J. Clin. Pathol. 60: 1403-1408.
*
-
Bush CR, Havens JM, Necela BM, Su W, Chen L, Yanagisawa M, Anastasiadis PZ, Guerra R, Luxon BA, Thompson EA 2007 Functional genomic analysis reveals crosstalk between peroxisome proliferator-activated receptor gamma (PPAR-gamma) and calcium signaling in human colorectal cancer cells.
J. Biol. Chem. 282: 23387-23401.
*
-
Byrd JC, Bresalier RS 2004 Mucins and mucin binding proteins in colorectal cancer.
Cancer Metastasis Rev. 23: 77-99.
*
-
Cabrera CM, Lopez-Nevot MA 2005 APC and chromosome instability in colorectal cancer.
Rev. Esp. Enferm. Dig. 97: 738-743.
-
Cacev T, Radosevic S, Spaventi R, Pavelic K, Kapitanovic S 2005 NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer.
Gut 54: 1129-1135.
*
-
Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, Ambudkar SV 2006 Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery.
Mol. Pharm. 3: 87-93.
-
Calviello G, Di Nicuolo F, Gragnoli S, Piccioni E, Serini S, Maggiano N, Tringali G, Navarra P, Ranelletti FO, Palozza P 2004 n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway.
Carcinogenesis 25: 2303-2310.
*
-
Calviello G, Resci F, Serini S, Piccioni E, Toesca A, Boninsegna A, Monego G, Ranelletti FO, Palozza P 2007 Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2.
Carcinogenesis 28: 1202-1209.
*
-
Camilleri M 2005 GIH clinical research update: 2004-2005.
Clin. Gastroenterol. Hepatol. 3: 1161-1166.
-
Camilleri M, Saito YA 2008 Pharmacogenomics in gastrointestinal disorders.
Methods Mol. Biol. 448: 395-412.
-
Campbell KS, Colonna M 2001 Human natural killer cell receptors and signal transduction.
Int. Rev. Immunol. 20: 333-370.
-
Campbell S, Ghosh S 2002 Ulcerative colitis and colon cancer: strategies for cancer prevention.
Dig. Dis. 20: 38-48.
-
Campregher C, Luciani MG, Gasche C 2008 Activated neutrophils induce an hMSH2-dependent G2/M checkpoint arrest and replication errors at a (CA)13-repeat in colon epithelial cells.
Gut 57: 780-787.
*
-
Canavan C, Abrams KR, Mayberry J 2006 Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease.
Aliment. Pharmacol. Ther. 23: 1097-1104.
*
-
Canter RJ, Kesmodel SB, Heitjan DF, Veeramachaneni NK, Mokadam NA, Drebin JA, Fraker DL 2005 Suppression of beta-catenin by antisense oligomers augments tumor response to isolated limb perfusion in a rodent model of adenomatous polyposis coli-mutant colon cancer.
Ann. Surg. Oncol. 12: 733-742.
*
-
Cao D, Wilentz RE, Abbruzzese JL, Ho L, Maitra A 2005 Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation.
Int. J. Gastrointest. Cancer 36: 39-46.
-
Cappell MS 2003 Colon cancer during pregnancy.
Gastroenterol. Clin. North Am. 32: 341-383.
*
-
Carrier J, Medline A, Sohn KJ, Choi M, Martin R, Hwang SW, Kim YI 2003 Effects of dietary folate on ulcerative colitis-associated colorectal carcinogenesis in the interleukin 2- and beta(2)-microglobulin-deficient mice.
Cancer Epidemiol. Biomarkers Prev. 12: 1262-1267.
*
-
Carson KL, Hunt CM 1997 Medical problems occurring after orthotopic liver transplantation.
Dig. Dis. Sci. 42: 1666-1674.
*
-
Catnach SM, Rutter KR, Bown RL 1993 Colorectal carcinoma in patients with ulcerative colitis and recent colonoscopy.
Gut 34: 1148-1149.
*
-
Ceol CJ, Pellman D, Zon LI 2007 APC and colon cancer: two hits for one.
Nat. Med. 13: 1286-1287.
*
-
Cereijido M, Contreras RG, Flores-Benítez D, Flores-Maldonado C, Larre I, Ruiz A, Shoshani L 2007 New diseases derived or associated with the tight junction.
Arch. Med. Res. 38: 465-478.
-
Cesario RM, Stone J, Yen WC, Bissonnette RP, Lamph WW 2006 Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer.
Cancer Lett. 240: 225-233.
*
-
Chambers WM, Warren BF, Jewell DP, McC Mortensen NJ 2005 Cancer surveillance in ulcerative colitis.
Br. J. Surg. 92: 928-936.
*
-
Chan JL, Tersmette AC, Offerhaus GJ, Gruber SB, Bayless TM, Giardiello FM 1999 Cancer risk in collagenous colitis.
Inflamm. Bowel Dis. 5: 40-43.
*
-
Chan TA 2006 Prostaglandins and the colon cancer connection.
Trends Mol. Med. 12: 240-244.
*
-
Chan TA 2002 Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention.
Lancet Oncol. 3: 166-174.
-
Chang DK, Kim YH, Byeon JS, Yang SK, Chung YW, Han DS, Kim SG, Kim TI, Kim WH, Jeen YT, Eun CS, Choi H, Choi KY, Song IS 2005 The current status of ulcerative colitis-associated colorectal cancer in Korea: a KASID study.
Korean J. Gastroenterol. 46: 276-282.
-
Chang SC, Lin PC, Lin JK, Yang SH, Wang HS, Fen-Yau Li A 2007 Role of MTHFR polymorphisms and folate levels in different phenotypes of sporadic colorectal cancers.
Int. J. Colorectal Dis. 22: 483-489.
*
-
Chang YT, Hsu C, Jeng YM, Chang MC, Wei SC, Wong JM 2007 Expression of the caudal-type homeodomain transcription factor CDX2 is related to clinical outcome in biliary tract carcinoma.
J. Gastroenterol. Hepatol. 22: 389-394.
*
-
Chapkin RS, Davidson LA, Ly L, Weeks BR, Lupton JR, McMurray DN 2007 Immunomodulatory effects of (n-3) fatty acids: putative link to inflammation and colon cancer.
J. Nutr. 137: 200S-204S.
*
-
Chapkin RS, McMurray DN, Lupton JR 2007 Colon cancer, fatty acids and anti-inflammatory compounds.
Curr. Opin. Gastroenterol. 23: 48-54.
-
Chapkin RS, Seo J, McMurray DN, Lupton JR 2008 Mechanisms by which docosahexaenoic acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine.
Chem. Phys. Lipids 153: 14-23.
*
-
Chapman RW 2006 High-dose UDCA in the treatment of primary sclerosing cholangitis.
Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 88-89. *
-
Chapman RW 2004 High dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 75. June 18-19. *
-
Chapman RW 2003 The management of primary sclerosing cholangitis.
Curr. Gastroenterol. Rep. 5: 9-17.
-
Chapman RW 2004 Novel approaches to the treatment of primary sclerosing cholangitis.
Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 72-73. *
-
Chapman RW 2006 Medical management of PSC: high dose vs low dose UDCA and bile duct dilatation.
Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 13-14. *
-
Chazouilleres O 2004 Primary sclerosing cholangitis and biliary malignancy: a glimmer of hope?
J. Hepatol. 40: 857-859.
*
-
Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC 2005 Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
J. Surg. Res. 124: 169-174.
*
-
Chen GG, Xu H, Lee JF, Subramaniam M, Leung KL, Wang SH, Chan UP, Spelsberg TC 2003 15-Hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferator-activated receptor gamma-dependent pathway.
Int. J. Cancer 107: 837-843.
*
-
Chen J, Compton C, Cheng E, Fromowitz F, Viola MV 1992 c-Ki-ras mutations in dysplastic fields and cancers in ulcerative colitis.
Gastroenterology 102: 1983-1987.
-
Chen R, Bronner MP, Crispin DA, Rabinovitch PS, Brentnall TA 2005 Characterization of genomic instability in ulcerative colitis neoplasia leads to discovery of putative tumor suppressor regions.
Cancer Genet. Cytogenet. 162: 99-106.
-
Chen R, Rabinovitch PS, Crispin DA, Emond MJ, Bronner MP, Brentnall TA 2005 The initiation of colon cancer in a chronic inflammatory setting.
Carcinogenesis 26: 1513-1519.
*
-
Chen R, Rabinovitch PS, Crispin DA, Emond MJ, Koprowicz KM, Bronner MP, Brentnall TA 2003 DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free.
Am. J. Pathol. 162: 665-672.
*
-
Chen SC, Rex DK 2007 Endoscopist can be more powerful than age and male gender in predicting adenoma detection at colonoscopy.
Am. J. Gastroenterol. 102: 856-861.
*
-
Chen W, Li D, Cannan RJ, Stubbs RS 2003 Common presence of Helicobacter DNA in the gallbladder of patients with gallstone diseases and controls.
Dig. Liver Dis. 35: 237-243.
-
Chen Y, Gan H, Ouyang Q, Xu D, Pan Y 2004 The effects of anti-inflammatory on activation of nuclear factor-kappaB and expression of cell adhesion molecules in patients with ulcerative colitis.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 21: 732-736.
-
Chen ZY, Istfan NW 2000 Docosahexaenoic acid is a potent inducer of apoptosis in HT-29 colon cancer cells.
Prostaglandins Leukot. Essent. Fatty Acids 63: 301-308.
*
-
Cheng HT, Chen JY, Huang YC, Chang HC, Hung WC 2006 Functional role of VDR in the activation of p27(Kip1) by the VDR/Sp1 complex.
J. Cell. Biochem. 98: 1450-1456.
*
-
Cheng JY, Meng CL, Chao CF, Gau SD, Lin JC 1993 Human papillomavirus 16 DNA in NIH3T3 cells transformed by colonic cancer cellular DNA.
Gut 34: 1710-1713.
*
-
Cheng XJ, Xu W, Zhang QY, Zhou RL 2008 Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers.
Ann. Oncol. 19: 527-532.
-
Cheng Y, Desreumaux P 2005 5-Aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.
World J. Gastroenterol. 11: 309-314.
*
-
Cheng Y, Tauschel HD, Nilsson A, Duan RD 1999 Ursodeoxycholic acid increases the activities of alkaline sphingomyelinase and caspase-3 in the rat colon.
Scand. J. Gastroenterol. 34: 915-920.
*
-
Chester KA, Robson L, Begent RH, Pringle H, Primrose L, Talbot IC, Macpherson AJ, Owen SL, Boxer G, Malcolm AD 1990 In situ and slot hybridization analysis of RNA in colorectal tumours and normal colon shows distinct distributions of mitochondrial sequences.
J. Pathol. 162: 309-315.
-
Chin MP, Schauer DB, Deen WM 2008 Prediction of nitric oxide concentrations in colonic crypts during inflammation.
Nitric Oxide May 3 [Epub ahead of print].
-
Chintharlapalli S, Papineni S, Jutooru I, McAlees A, Safe S 2007 Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor gamma agonists in colon cancer cells.
Mol. Cancer Ther. 6: 1588-1598.
-
Chintharlapalli S, Papineni S, Safe S 2006 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARgamma-dependent and PPARgamma-independent pathways.
Mol. Cancer Ther. 5: 1362-1370.
-
Chiu HM, Lin JT, Shun CT, Liang JT, Lee YC, Huang SP, Wu MS 2007 Association of metabolic syndrome with proximal and synchronous colorectal neoplasm.
Clin. Gastroenterol. Hepatol. 5: 221-229.
-
Cho J 2000 Update on inflammatory bowel disease genetics.
Curr. Gastroenterol. Rep. 2: 434-439.
-
Cho JH 2001 Update on the genetics of inflammatory bowel disease.
Curr. Gastroenterol. Rep. 3: 458-463.
-
Choe JW, Chang HS, Yang SK, Myung SJ, Byeon JS, Lee D, Song HK, Lee HJ, Chung EJ, Kim SY, Jung HY, Lee GH, Hong WS, Kim JH, Min YI 2007 Screening colonoscopy in asymptomatic average-risk Koreans: analysis in relation to age and sex.
J. Gastroenterol. Hepatol. 22: 1003-1008.
*
-
Choi IK, Kim YH, Kim JS, Seo JH 2008 PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo.
Invest. New Drugs 26: 283-288.
-
Choi PM, Kim WH 1995 Colon cancer surveillance.
Gastroenterol. Clin. North Am. 24: 671-687.
-
Choi PM, Nugent FW, Schoetz DJ Jr, Silverman ML, Haggitt RC 1993 Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis.
Gastroenterology 105: 418-424.
-
Cholongitas E, Papatheodoridis GV, Zappoli P, Giannakopoulos A, Patch D, Marelli L, Shusang V, Kalambokis G, Shirling G, Rolando N, Burroughs AK 2007 Combined HLA-DR and -DQ disparity is associated with a stable course of ulcerative colitis after liver transplantation for primary sclerosing cholangitis.
Liver Transpl. 13: 552-557.
*
-
Chourasia MK, Jain SK 2003 Pharmaceutical approaches to colon targeted drug delivery systems.
J. Pharm. Pharm. Sci. 6: 33-66.
*
-
Choy P, Bissett I, Docherty J, Parry B, Merrie A 2007 Stapled versus handsewn methods for ileocolic anastomoses.
Cochrane Database Syst. Rev. 3: CD004320.
*
-
Christl SU, Eisner HD, Dusel G, Kasper H, Scheppach W 1996 Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis.
Dig. Dis. Sci. 41: 2477-2481.
-
Chu EC, Chai J, Ahluwalia A, Tarnawski AS 2007 Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action?
Aliment. Pharmacol. Ther. 25: 1443-1449.
*
-
Chung SK, Lee MG, Ryu BK, Lee JH, Han J, Byun DS, Chae KS, Lee KY, Jang JY, Kim HJ, Chi SG 2007 Frequent alteration of XAF1 in human colorectal cancers: implication for tumor cell resistance to apoptotic stresses.
Gastroenterology 132: 2459-2477.
*
-
Church RD, Fleshman JW, McLeod HL 2003 Cyclo-oxygenase 2 inhibition in colorectal cancer therapy.
Br. J. Surg. 90: 1055-1067.
*
-
Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M; Italian Multicentre Study Group 2001 Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence.
Gut 48: 812-815.
*
-
Clapper ML, Adrian RH, Pfeiffer GR, Kido K, Everley L, Cooper HS, Murthy S 1999 Depletion of colonic detoxication enzyme activity in mice with dextran sulphate sodium-induced colitis.
Aliment. Pharmacol. Ther. 13: 389-396.
*
-
Clapper ML, Szarka CE 1998 Glutathione S-transferases - biomarkers of cancer risk and chemopreventive response.
Chem. Biol. Interact. 111-112: 377-388.
-
Clevers H 2006 Colon cancer - understanding how NSAIDs work.
N. Engl. J. Med. 354: 761-763.
*
-
Coatmeur O, Rassiat E, Bonniaud P, Jouve JL, Minello A, Bedenne L, Faivre J, Hillon P 2004 Acute pseudo-angiocholitis due to colonic adenocarcinoma in a man with primary sclerosis cholangitis and ulcerative colitis.
Ann. Med. Interne. (Paris) 154: 547-548.
-
Coban S, Yuksel O, Kockar MC, Koklu S, Basar O, Tutkak H, Ormeci N 2007 The significance of serum transforming growth factor beta 1 in detecting of gastric and colon cancers.
Hepatogastroenterology 54: 1472-1476.
-
Coggins RP, Cawkwell L, Bell SM, Crockford GP, Quirke P, Finan PJ, Bishop DT 2005 Association between family history and mismatch repair in colorectal cancer.
Gut 54: 636-642.
*
-
Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, et al 2007 Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
JAMA 297: 2351-2359.
*
-
Coleman LJ, Landstrom EK, Royle PJ, Bird AR, McIntosh GH 2002 A diet containing alpha-cellulose and fish oil reduces aberrant crypt foci formation and modulates other possible markers for colon cancer risk in azoxymethane-treated rats.
J. Nutr. 132: 2312-2318.
*
-
Collett ED, Davidson LA, Fan YY, Lupton JR, Chapkin RS 2001 n-6 and n-3 polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes.
Am. J. Physiol. Cell. Physiol. 280: C1066-C1075.
*
-
Collins P, Mpofu C, Watson A, Rhodes J 2006 Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease.
Cochrane Database Syst. Rev. 2: CD000279.
*
-
Colliver DW, Crawford NP, Eichenberger MR, Zacharius W, Petras RE, Stromberg AJ, Galandiuk S 2006 Molecular profiling of ulcerative colitis-associated neoplastic progression.
Exp. Mol. Pathol. 80: 1-10.
*
-
Colonna M, Bresnahan M, Bahram S, Strominger JL, Spies T 1992 Allelic variants of the human putative peptide transporter involved in antigen processing.
Proc. Natl. Acad. Sci. U.S.A. 89: 3932-3936.
*
-
Colquhoun P, Chen HC, Kim JI, Efron J, Weiss EG, Nogueras JJ, Vernava AM, Wexner SD 2004 High compliance rates observed for follow up colonoscopy post polypectomy are achievable outside of clinical trials: efficacy of polypectomy is not reduced by low compliance for follow up.
Colorectal Dis. 6: 158-161.
-
Conney AH 2004 Tailoring cancer chemoprevention regimens to the individual.
J. Cell. Biochem. 91: 277-286.
*
-
Consolazio A, Al Ograve PL, Rivera M, Iacopini F, Paoluzi OA, Crispino P, Pica R, Paoluzi P 2006 Overexpression of fatty acid synthase in ulcerative colitis.
Am. J. Clin. Pathol. 126: 1-6.
*
-
Coogan PF, Rosenberg L 2007 The use of folic acid antagonists and the risk of colorectal cancer.
Pharmacoepidemiol. Drug Saf. 16: 1111-1119.
-
Costantini R, De Nicola P, Bianco F, Cotroneo AR, Iezzi R, Di Bartolomeo N, Innocenti P 2007 Tumor vs non-tumor origin of occult and obscure gastrointestinal bleeding requiring hospitalization.
Tumori 93: 461-466.
-
Courtney ED, Matthews S, Finlayson C, Di Pierro D, Belluzzi A, Roda E, Kang JY, Leicester RJ 2007 Eicosapentaenoic acid (EPA) reduces crypt cell proliferation and increases apoptosis in normal colonic mucosa in subjects with a history of colorectal adenomas.
Int. J. Colorectal Dis. 22: 765-776.
*
-
Couzin J 2006 Cancer. T cells a boon for colon cancer prognosis.
Science 313: 1868-1869.
*
-
Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, Tallada M, Garrido F, Ruiz-Cabello F 2007 High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer.
Hum. Immunol. 68: 698-704.
-
Crabtree MD, Fletcher C, Churchman M, Hodgson SV, Neale K, Phillips RK, Tomlinson IP 2004 Analysis of candidate modifier loci for the severity of colonic familial adenomatous polyposis, with evidence for the importance of the N-acetyl transferases.
Gut 53: 271-276.
*
-
Cravo ML, Mason JB, Dayal Y, Hutchinson M, Smith D, Selhub J, Rosenberg IH 1992 Folate deficiency enhances the development of colonic neoplasia in dimethylhydrazine-treated rats.
Cancer Res. 52: 5002-5006.
*
-
Cremers MI, Marques-Vidal P; NGHD (Nucleo de Gastrenterologia dos Hospitais Distritais) 2006 Colonoscopies in Portuguese district hospitals: a multicentric transverse study.
Dig. Liver Dis. 38: 912-917.
-
Crowley-Weber CL, Dvorakova K, Crowley C, Bernstein H, Bernstein C, Garewal H, Payne CM 2003 Nicotine increases oxidative stress, activates NF-kappaB and GRP78, induces apoptosis and sensitizes cells to genotoxic/xenobiotic stresses by a multiple stress inducer, deoxycholate: relevance to colon carcinogenesis.
Chem. Biol. Interact. 145: 53-66.
*
-
Crowley-Weber CL, Payne CM, Gleason-Guzman M, Watts GS, Futscher B, Waltmire CN, Crowley C, Dvorakova K, Bernstein C, Craven M, Garewal H, Bernstein H 2002 Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate.
Carcinogenesis 23: 2063-2080.
*
-
Curtin K, Bigler J, Slattery ML, Caan B, Potter JD, Ulrich CM 2004 MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer.
Cancer Epidemiol. Biomarkers Prev. 13: 285-292.
*
-
Curtin K, Ulrich CM, Samowitz WS, Bigler J, Caan B, Potter JD, Slattery ML 2007 Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival.
Int. J. Cancer 120: 2226-2232.
*
-
Czito BG, Hong TJ, Cohen DP, Tyler DS, Lee CG, Anscher MS, Ludwig KA, Seigler HF, Mantyh C, Morse MA, Lockhart AC, Petros WP, Honeycutt W, Spector NL, Ertel PJ, Mangum SG, Hurwitz HI 2004 A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
Int. J. Radiat. Oncol. Biol. Phys. 58: 779-785.
-
D'Argenio G, Calvani M, Della Valle N, Cosenza V, Di Matteo G, Giorgio P, Margarucci S, Petillo O, Jori FP, Galderisi U, Peluso G 2005 Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis.
Gut 54: 496-502.
*
-
D'Inca R, Cardin R, Benazzato L, Angriman I, Martines D, Sturniolo GC 2004 Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia.
Inflamm. Bowel Dis. 10: 23-27.
*
-
da Silva JG, De Brito T, Cintra Damiao AO, Laudanna AA, Sipahi AM 2006 Histologic study of colonic mucosa in patients with chronic diarrhea and normal colonoscopic findings.
J. Clin. Gastroenterol. 40: 44-48.
-
DaCosta RS, Wilson BC, Marcon NE 2005 Optical techniques for the endoscopic detection of dysplastic colonic lesions.
Curr. Opin. Gastroenterol. 21: 70-79.
-
Dafnis G, Blomqvist P, Granath F, Pahlman L, Ekbom A 2003 Colorectal cancer detection by colonoscopy in a Swedish county, 1979-95.
Scand. J. Gastroenterol. 38: 1059-1067.
*
-
Dafnis G, Blomqvist P, Pahlman L, Ekbom A 2000 The introduction and development of colonoscopy within a defined population in Sweden.
Scand. J. Gastroenterol. 35: 765-771.
*
-
Daftarian P, Song GY, Ali S, Faynsod M, Longmate J, Diamond DJ, Ellenhorn JD 2004 Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
Cancer Res. 64: 5407-5414.
*
-
Dalgleish AG, O'Byrne K 2006 Inflammation and cancer: the role of the immune response and angiogenesis.
Cancer Treat. Res. 130: 1-38.
-
Danese S 2008 Inflammatory bowel disease and inflammation-associated colon cancer: partners in crime.
Curr. Drug Targets 9: 360.
-
Dang CT, Shapiro CL, Hudis CA 2002 Potential role of selective COX-2 inhibitors in cancer management.
Oncology (Huntingt.) 16: 30-36.
-
Daniel C, Schroder O, Zahn N, Gaschott T, Steinhilber D, Stein JM 2007 The TGFbeta/Smad 3-signaling pathway is involved in butyrate-mediated vitamin D receptor (VDR)-expression.
J. Cell. Biochem. 102: 1420-1431.
-
Dannenberg AJ, Zakim D 1999 Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2.
Semin. Oncol. 26: 499-504.
-
Daperno M, Sostegni R, Lavagna A, Crocella L, Ercole E, Rigazio C, Rocca R, Pera A 2004 The role of endoscopy in inflammatory bowel disease.
Eur. Rev. Med. Pharmacol. Sci. 8: 209-214.
-
Darragh J, Hunter M, Pohler E, Nelson L, Dillon JF, Nenutil R, Vojtesek B, Ross PE, Kernohan N, Hupp TR 2006 The calcium-binding domain of the stress protein SEP53 is required for survival in response to deoxycholic acid-mediated injury.
FEBS J. 273: 1930-1947.
*
-
Das D, Arber N, Jankowski JA 2007 Chemoprevention of colorectal cancer.
Digestion 76: 51-67.
-
Das KM, Sakamaki S, Vecchi M 1989 Ulcerative colitis: specific antibodies against a colonic epithelial Mr 40,000 protein.
Immunol. Invest. 18: 459-472.
-
Das KM, Squillante L, Robertson F 1992 Expression of the 40 kD protein in DLD-1 colon cancer cells and the effect of cytokines.
Clin. Exp. Immunol. 88: 138-142.
*
-
Das KM, Vecchi M, Squillante L, Dasgupta A, Henke M, Clapp N 1992 Mr 40,000 human colonic epithelial protein expression in colonic mucosa and presence of circulating anti-Mr 40,000 antibodies in cotton top tamarins with spontaneous colitis.
Gut 33: 48-54.
*
-
Dassopoulos T 2001 Diagnostic methodologies: serology, endoscopy, and radiology.
Curr. Gastroenterol. Rep. 3: 491-499.
-
Davidson LA, Nguyen DV, Hokanson RM, Callaway ES, Isett RB, Turner ND, Dougherty ER, Wang N, Lupton JR, Carroll RJ, Chapkin RS 2004 Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat.
Cancer Res. 64: 6797-6804.
*
-
Davies E, Tsang CW, Ghazali AR, Harris RM, Waring RH 2004 Effects of culture with TNF-alpha, TGF-beta and insulin on sulphotransferase (SULT 1A1 and 1A3) activity in human colon and neuronal cell lines.
Toxicol. In Vitro 18: 749-754.
-
Davis AE, Patterson F, Crouch R 1992 The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model.
Br. J. Cancer 66: 777-780.
-
Dayal B, Ertel NH 1997 Studies on N-nitroso bile acid amides in relation to their possible role in gastrointestinal cancer.
Lipids 32: 1331-1340.
-
De Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, Ventre G, Bentzen CL, Niesor EJ, Dufour JF 2004 The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer.
Dig. Dis. Sci. 49: 982-989.
*
-
de Jong DJ, Nagengast FM 2007 Tracing colorectal carcinoma in patients with inflammatory bowel disease.
Ned. Tijdschr. Geneeskd. 151: 2758-2760.
-
de Jong MM, Niens M, Nolte IM, Te Meerman GJ, van der Graaf WT, Mulder MJ, van der Steege G, Bruinenberg M, Schaapveld M, Sijmons RH, Hofstra RM, de Vries EG, Kleibeuker JH 2005 The human leukocyte antigen region and colorectal cancer risk.
Dis. Colon Rectum 48: 303-306.
*
-
De la Fuente MK, Alvarez KP, Letelier AJ, Bellolio F, Acuna ML, Leon FS, Pinto E, Carvallo P, Lopez-Kostner F 2007 Mutational screening of the APC gene in Chilean families with familial adenomatous polyposis: nine novel truncating mutations.
Dis. Colon Rectum 50: 2142-2148.
*
-
De La Rue SA, Bickston SJ 2006 Evidence-based medications for the treatment of the inflammatory bowel diseases.
Curr. Opin. Gastroenterol. 22: 365-369.
-
de Moreno de Leblanc A, Perdigon G 2004 Yogurt feeding inhibits promotion and progression of experimental colorectal cancer.
Med. Sci. Monit. 10: BR96-BR104.
*
-
De Vos Tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G, Cats A, Morreau H, Gelderblom H, Vasen HF 2004 Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer.
Int. J. Cancer 109: 468-471.
*
-
de Vrese M, Schrezenmeir J 2008 Probiotics, prebiotics, and synbiotics.
Adv. Biochem. Eng. Biotechnol. 111: 1-66.
*
-
Decensi A, Costa A 2000 Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer.
Eur. J. Cancer 36: 694-709.
*
-
Dekker E, van den Broek FJ, Reitsma JB, Hardwick JC, Offerhaus GJ, van Deventer SJ, Hommes DW, Fockens P 2007 Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis.
Endoscopy 39: 216-221.
-
Del Poggio P, Buonocore M 2008 Cystic tumors of the liver: a practical approach.
World J. Gastroenterol. 14: 3616-3620.
*
-
Delco F, Sonnenberg A 1999 The unsolved problem of surveillance for colorectal cancer in ulcerative colitis.
Can. J. Gastroenterol. 13: 655-660.
-
Delco F, Sonnenberg A 2000 A decision analysis of surveillance for colorectal cancer in ulcerative colitis.
Gut 46: 500-506.
*
-
Delgado Plasencia L, Arteaga Gonzalez I, Lopez-Tomassetti Fernandez EM, Martin Malagon A, Diaz Luis H, Carrillo Pallares A 2006 Restorative proctocolectomy with an ileoanal pouch: the role of laparoscopy.
Rev. Esp. Enferm. Dig. 98: 420-428.
-
Delvaux M, Gay G 2008 Capsule endoscopy: technique and indications.
Best Pract. Res. Clin. Gastroenterol. 22: 813-837.
-
Demols A, Van Laethem JL, Gay F, Franchimont D, Adler M, Van Gossum A 2001 Individual screening for colorectal cancer: which strategy for which patient?
Rev. Med. Brux. 22: A203-A209.
-
Dempke W, Rie C, Grothey A, Schmoll HJ 2001 Cyclooxygenase-2: a novel target for cancer chemotherapy?
J. Cancer Res. Clin. Oncol. 127: 411-417.
*
-
Der G, Love T, Schreck J, Horn M 2005 Primary sclerosing cholangitis: a case presentation.
Gastroenterol. Nurs. 28: 13-16.
*
-
Desreumaux P, Ghosh S 2006 Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.
Aliment. Pharmacol. Ther. 24 Suppl. 1: 2-9.
*
-
Deutscher N, Bataille F, Hausmann M, Kiessling S, Muller-Newen G, Leeb SN, Herfarth H, Heinrich PC, Scholmerich J, Rogler G 2006 Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer.
Int. J. Colorectal Dis. 21: 573-581.
*
-
Dhar A, Johnson KS, Novelli MR, Bown SG, Bigio IJ, Lovat LB, Bloom SL 2006 Elastic scattering spectroscopy for the diagnosis of colonic lesions: initial results of a novel optical biopsy technique.
Gastrointest. Endosc. 63: 257-261.
-
Di Mari JF, Saada JI, Mifflin RC, Valentich JD, Powell DW 2007 HETEs enhance IL-1-mediated COX-2 expression via augmentation of message stability in human colonic myofibroblasts.
Am. J. Physiol. Gastrointest. Liver Physiol. 293: G719-G728.
*
-
Dietrich CG, Geier A, Wasmuth HE, Matern S, Gartung C, de Waart DR, Elferink RP 2004 Influence of biliary cirrhosis on the detoxification and elimination of a food derived carcinogen.
Gut 53: 1850-1855.
*
-
Dikengil A, Siskind BN, Morse SS, Swedlund A, Bober-Sorcinelli KE, Burrell MI 1986 Sclerosing cholangitis from intraarterial floxuridine.
J. Clin. Gastroenterol. 8: 690-693.
-
Dillard AC, Lane MA 2007 Retinol decreases beta-catenin protein levels in retinoic acid-resistant colon cancer cell lines.
Mol. Carcinog. 46: 315-329.
*
-
Dillard AC, Lane MA 2008 Retinol increases beta-catenin-RXRalpha binding leading to the increased proteasomal degradation of beta-catenin and RXRalpha.
Nutr. Cancer 60: 97-108.
-
Dilmec F, Ozgonul A, Uzunkoy A, Akkafa F 2008 Investigation of CTLA-4 and CD28 gene polymorphisms in a group of Turkish patients with colorectal cancer.
Int. J. Immunogenet. Aug 1 [Epub ahead of print].
-
Dimberg J, Hugander A, Lofgren S, Wagsater D 2007 Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients.
Int. J. Mol. Med. 19: 11-15.
*
-
Dincer Y, Erzin Y, Himmetoglu S, Gunes KN, Bal K, Akcay T 2007 Oxidative DNA damage and antioxidant activity in patients with inflammatory bowel disease.
Dig. Dis. Sci. 52: 1636-1641.
*
-
Ding YJ, Yu JP, Luo HS, Zhou ZY, Liu J 2006 Evaluation and analysis of colonoscopy in the diagnosis of 186 cases of ulcerative colitis patients.
Int. J. Clin. Pract. 60: 1408-1410.
*
-
Dippold W, Wittig B, Schwaeble W, Mayet W, Meyer zum Büschenfelde KH 1993 Expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in colonic epithelial cells.
Gut 34: 1593-1597.
*
-
Divisi D, Di Tommaso S, Salvemini S, Garramone M, Crisci R 2006 Diet and cancer.
Acta Biomed. Ateneo. Parmense. 77: 118-123.
-
Dixon A, Wurm P, Hart A, Robinson R 2006 Distal adenomatous polyps are rare in patients with inflammatory bowel disease.
Postgrad. Med. J. 82: 76-78.
*
-
Dobrovolskaia MA, Kozlov SV 2005 Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership.
Curr. Cancer Drug Targets 5: 325-344.
-
Dommels YE, Haring MM, Keestra NG, Alink GM, van Bladeren PJ, van Ommen B 2003 The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE(2) synthesis and cytotoxicity in human colorectal carcinoma cell lines.
Carcinogenesis 24: 385-392.
*
-
Dorer R, Odze RD 2006 AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Am. J. Surg. Pathol. 30: 871-877.
-
Doria-Rose VP, Levin TR, Selby JV, Newcomb PA, Richert-Boe KE, Weiss NS 2004 The incidence of colorectal cancer following a negative screening sigmoidoscopy: implications for screening interval.
Gastroenterology 127: 714-722.
*
-
Dorner AJ, Goldman SJ, Keith Jr JC 1997 Interleukin-11.
BioDrugs 8: 418-429.
-
Doron S, Gorbach SL 2006 Probiotics: their role in the treatment and prevention of disease.
Expert Rev. Anti Infect. Ther. 4: 261-275.
-
Dossett LA, White LM, Welch DC, Herline AJ, Muldoon RL, Schwartz DA, Wise PE 2007 Small bowel adenocarcinoma complicating Crohn's disease: case series and review of the literature.
Am. Surg. 73: 1181-1187.
-
Dove-Edwin I, Thomas HJ 2001 Review article: the prevention of colorectal cancer.
Aliment. Pharmacol. Ther. 15: 323-336.
*
-
Doyle LA, Ross DD 2003 Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene 22: 7340-7358.
*
-
Dozois EJ, Boardman LA, Suwanthanma W, Limburg PJ, Cima RR, Bakken JL, Vierkant RA, Aakre JA, Larson DW 2008 Young-onset colorectal cancer in patients with no known genetic predisposition: can we increase early recognition and improve outcome?
Medicine (Baltimore) 87: 259-263.
-
Drew JE, Arthur JR, Farquharson AJ, Russell WR, Morrice PC, Duthie GG 2005 Salicylic acid modulates oxidative stress and glutathione peroxidase activity in the rat colon.
Biochem. Pharmacol. 70: 888-893.
*
-
Drew JE, Farquharson AJ, Arthur JR, Morrice PC, Duthie GG 2005 Novel sites of cytosolic glutathione peroxidase expression in colon.
FEBS Lett. 579: 6135-6139.
*
-
Drew JE, Padidar S, Horgan G, Duthie GG, Russell WR, Reid M, Duncan G, Rucklidge GJ 2006 Salicylate modulates oxidative stress in the rat colon: a proteomic approach.
Biochem. Pharmacol. 72: 204-216.
*
-
Du JX, Bialkowska AB, McConnell BB, Yang VW 2008 Sumoylation regulates nuclear localization of Kruppel-like factor 5.
J. Biol. Chem. Sep 9 [Epub ahead of print].
*
-
Duan RD 2006 Alkaline sphingomyelinase: an old enzyme with novel implications.
Biochim. Biophys. Acta 1761: 281-291.
*
-
Duan RD, Cheng Y, Tauschel HD, Nilsson A 1998 Effects of ursodeoxycholate and other bile salts on levels of rat intestinal alkaline sphingomyelinase: a potential implication in tumorigenesis.
Dig. Dis. Sci. 43: 26-32.
*
-
DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA 1998 The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers.
Carcinogenesis 19: 49-53.
*
-
Dumonceau JM, Macias Gomez C, Casco C, Genevay M, Marcolongo M, Bongiovanni M, Morel P, Majno P, Hadengue A 2007 Grasp or brush for biliary sampling at endoscopic retrograde cholangiography? A blinded randomized controlled trial.
Am. J. Gastroenterol. 103: 333-340.
*
-
Dundar M, Caglayan AO, Saatci C, Karaca H, Baskol M, Tahiri S, Ozkul Y 2007 How the I1307K adenomatous polyposis coli gene variant contributes in the assessment of risk of colorectal cancer, but not stomach cancer, in a Turkish population.
Cancer Genet. Cytogenet. 177: 95-97.
-
Dupertuis YM, Meguid MM, Pichard C 2007 Colon cancer therapy: new perspectives of nutritional manipulations using polyunsaturated fatty acids.
Curr. Opin. Clin. Nutr. Metab. Care 10: 427-432.
-
Dvorchik I, Subotin M, Demetris AJ, Fung JJ, Starzl TE, Wieand S, Abu-Elmagd KM 2002 Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis.
Hepatology 35: 380-384.
*
-
Dysager L, Jensen LH, Lindebjerg J, Jakobsen A 2008 The prognostic importance of thymidylate gene polymorphism in colon cancer stage II.
Int. J. Colorectal Dis. Jul 16 [Epub ahead of print].
*
-
Eaden J 2004 Colorectal carcinoma and inflammatory bowel disease.
Aliment. Pharmacol. Ther. 20 Suppl. 4: 24-30.
*
-
Eaden JA, Ward BA, Mayberry JF 2000 How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance.
Gastrointest. Endosc. 51: 123-128.
*
-
Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, Roy H, Khare S, Brasitus TA 1994 Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid.
Cancer Res. 54: 5071-5074.
*
-
Eastwood GL 1996 Pharmacologic prevention of colonic neoplasms. Effects of calcium, vitamins, omega fatty acids, and nonsteroidal anti-inflammatory drugs.
Dig. Dis. 14: 119-128.
-
Ebert EC, Groh V 2008 Dissection of spontaneous cytotoxicity by human intestinal intraepithelial lymphocytes: MIC on colon cancer triggers NKG2D-mediated lysis through Fas ligand.
Immunology 124: 33-41.
*
-
Edelblum KL, Goettel JA, Koyama T, McElroy SJ, Yan F, Polk DB 2008 TNFR1 promotes TNF-mediated mouse colon epithelial cell survival through Raf activation of NF-kappa B.
J. Biol. Chem. Aug 18 [Epub ahead of print].
*
-
Edwards RA, Smock AZ 2006 Defective arachidonate release and PGE2 production in Gialpha2-deficient intestinal and colonic subepithelial myofibroblasts.
Inflamm. Bowel Dis. 12: 153-165.
*
-
Edwards RA, Wang K, Davis JS, Birnbaumer L 2008 Role for epithelial dysregulation in early-onset colitis-associated colon cancer in Gi2-alpha-/- mice.
Inflamm. Bowel Dis. 14: 898-907.
-
Eisinger AL, Nadauld LD, Shelton DN, Prescott SM, Stafforini DM, Jones DA 2007 Retinoic acid inhibits beta-catenin through suppression of Cox-2: a role for truncated adenomatous polyposis coli.
J. Biol. Chem. 282: 29394-29400.
*
-
Ekbom A 2006 Can we predict the natural history of IBD?
Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, pp. 29-30. *
-
Ekbom A, Helmick C, Zack M, Adami HO 1990 Ulcerative colitis and colorectal cancer. A population-based study.
N. Engl. J. Med. 323: 1228-1233.
-
Ekbom A, Helmick C, Zack M, Adami HO 1991 Extracolonic malignancies in inflammatory bowel disease.
Cancer 67: 2015-2019.
-
El-Bayoumy K, Sinha R 2005 Molecular chemoprevention by selenium: a genomic approach.
Mutat. Res. 591: 224-236.
-
Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT 2007 Masquerader: high mobility group box-1 and cancer.
Clin. Cancer Res. 13: 2836-2848.
*
-
Endo Y, Marusawa H, Kou T, Nakase H, Fujii S, Fujimori T, Kinoshita K, Honjo T, Chiba T 2008 Activation-induced cytidine deaminase: links between inflammation and the development of colitis-associated colorectal cancers.
Gastroenterology 135: 889-898.e3.
*
-
Engelbrecht AM, Toit-Kohn JL, Ellis B, Thomas M, Nell T, Smith R 2008 Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model.
Apoptosis Sep 11 [Epub ahead of print].
-
Engi H, Gyemant N, Lorand T, Levai A, Ocsovszki I, Molnar J 2006 Cinnamylidene ketones as potential modulators of multidrug resistance in mouse lymphoma and human colon cancer cell lines.
In Vivo 20: 119-124.
-
Enzler T, Gillessen S, Dougan M, Allison JP, Neuberg D, Oble DA, Mihm M, Dranoff G 2007 Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta-cells.
Blood 110: 954-961.
*
-
Erdman SE, Poutahidis T, Tomczak M, Rogers AB, Cormier K, Plank B, Horwitz BH, Fox JG 2003 CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice.
Am. J. Pathol. 162: 691-702.
*
-
Erdman SE, Rao VP, Poutahidis T, Ihrig MM, Ge Z, Feng Y, Tomczak M, Rogers AB, Horwitz BH, Fox JG 2003 CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice.
Cancer Res. 63: 6042-6050.
*
-
Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ 2004 C-reactive protein and the risk of incident colorectal cancer.
JAMA 291: 585-590.
*
-
Esteban E, Via M, Gonzalez-Perez E, Santamaria J, Dugoujon JM, Vona G, Harich N, Luna F, Saetta AA, Bissar N, Moral P 2005 An unexpected wide population variation of the G1733A polymorphism of the androgen receptor gene: data on the Mediterranean region.
Am. J. Hum. Biol. 17: 690-695.
-
Evans JA, Nishioka NS 2005 Endoscopic confocal microscopy.
Curr. Opin. Gastroenterol. 21: 578-584.
-
Ewald N, Toepler M, Akinci A, Kloer HU, Bretzel RG, Hardt PD 2005 Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review.
Z. Gastroenterol. 43: 1313-1317.
-
Eyles JL, Roberts AW, Metcalf D, Wicks IP 2006 Granulocyte colony-stimulating factor and neutrophils-forgotten mediators of inflammatory disease.
Nat. Clin. Pract. Rheumatol. 2: 500-510.
*
-
Faioni EM, Ferrero S, Fontana G, Gianelli U, Ciulla MM, Vecchi M, Saibeni S, Biguzzi E, Cordani N, Franchi F, Bosari S, Cattaneo M 2004 Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease.
Crit. Care Med. 32: S266-S270.
-
Fallingborg JF 2006 Does 5-ASA prevent development of colon cancer in patients with ulcerative colitis?
Ugeskr. Laeger. 168: 2049-2051.
-
Fan J, Peng Z, Zhou C, Qiu G, Tang H, Sun Y, Wang X, Li Q, Le X, Xie K 2008 Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genomewide gene-expression analyses: identification and validation of IFITM3 as a biomarker of early colon carcinogenesis.
Cancer 113: 266-275.
-
Fan YY, Spencer TE, Wang N, Moyer MP, Chapkin RS 2003 Chemopreventive n-3 fatty acids activate RXRalpha in colonocytes.
Carcinogenesis 24: 1541-1548.
*
-
Fang C, Dean J, Smith JW 2007 A novel variant of ileal bile acid binding protein is up-regulated through nuclear factor-kappaB activation in colorectal adenocarcinoma.
Cancer Res. 67: 9039-9046.
*
-
Farkas A, Tonel G, Nestle FO 2008 Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells.
Br. J. Dermatol. 158: 921-929.
*
-
Farkas S, Hornung M, Sattler C, Guba M, Steinbauer M, Anthuber M, Herfarth H, Schlitt HJ, Geissler EK 2006 Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis.
Int. J. Colorectal Dis. 21: 747-753.
*
-
Fazio L, Cotterchio M, Manno M, McLaughlin J, Gallinger S 2005 Association between colonic screening, subject characteristics, and stage of colorectal cancer.
Am. J. Gastroenterol. 100: 2531-2539.
*
-
Fedorak RN, Penner R, Madsen KL 2006 Probiotics in the treatment of gastrointestinal diseases.
US Gastroenterology Review, p. 28-31. *
-
Feld AD 2004 Malpractice risks associated with colon cancer and inflammatory bowel disease.
Am. J. Gastroenterol. 99: 1641-1644.
*
-
Feld J, Heathcote E 2003 Epidemiology of autoimmune liver disease.
J. Gastroenterol. Hepatol. 18: 1118-1128.
*
-
Fernandez E, Gallus S, La Vecchia C 2006 Nutrition and cancer risk: an overview.
J. Br. Menopause Soc. 12: 139-142.
-
Fernandez-Urien I, Carretero C, Borda A, Munoz-Navas M 2008 Colon capsule endoscopy.
World J. Gastroenterol. 14: 5265-5268.
*
-
Ferracin M, Gafa R, Miotto E, Veronese A, Pultrone C, Sabbioni S, Lanza G, Negrini M 2008 The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile.
J. Pathol. 214: 594-602.
*
-
Ferrandez A, Prescott S, Burt RW 2003 COX-2 and colorectal cancer.
Curr. Pharm. Des. 9: 2229-2251.
-
Ferrandez A, Samowitz W, DiSario JA, Burt RW 2004 Phenotypic characteristics and risk of cancer development in hyperplastic polyposis: case series and literature review.
Am. J. Gastroenterol. 99: 2012-2018.
*
-
Ferstl FJ, Obert R 2004 Computed tomography (CT) of acute diverticulitis of the cecum and ascending colon.
Rofo. 176: 1257-1264.
-
Fiatte C, Huin C, Bertin I, Lesuffleur T, Pluvinet A, Touche N, Plenat F, Dauca M, Domenjoud L, Schohn H 2006 Genetic analysis of peroxisome proliferator-activated receptor gamma1 splice variants in human colorectal cell lines.
Int. J. Oncol. 29: 1601-1610.
*
-
Fidder HH, Figer A, Geva R, Flex D, Schayek H, Avidan B, Meir SB, Friedman E 2005 Genetic analyses in consecutive Israeli Jewish colorectal cancer patients.
Am. J. Gastroenterol. 100: 1376-1380.
*
-
Fife RS, Stott B, Carr RE 2004 Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro.
Cancer Biol. Ther. 3: 228-232.
*
-
Figer A, Irmin L, Geva R, Flex D, Sulkes J, Sulkes A, Friedman E 2001 The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel.
Br. J. Cancer 84: 478-481.
*
-
Filipovic BR, Filipovic BF, Kerkez M, Milinic N, Randelovic T 2007 Depression and anxiety levels in therapy-naive patients with inflammatory bowel disease and cancer of the colon.
World J. Gastroenterol. 13: 438-443.
*
-
Finch R, Moore HG, Lindor N, Jalal SM, Markowitz A, Jhanwar S, Offit K, Guillem JG 2005 Familial adenomatous polyposis and mental retardation caused by a de novo chromosomal deletion at 5q15-q22: report of a case.
Dis. Colon Rectum 48: 2148-2152.
*
-
Fisher DA, Judd L, Sanford NS 2005 Inappropriate colorectal cancer screening: findings and implications.
Am. J. Gastroenterol. 100: 2526-2530.
*
-
Fletcher JG, Booya F, Johnson CD, Ahlquist D 2005 CT colonography: unraveling the twists and turns.
Curr. Opin. Gastroenterol. 21: 90-98.
-
Floreani A, Zancan L, Melis A, Baragiotta A, Chiaramonte M 1999 Primary sclerosing cholangitis (PSC): clinical, laboratory and survival analysis in children and adults.
Liver 19: 228-233.
-
Foltz CJ, Fox JG, Cahill R, Murphy JC, Yan L, Shames B, Schauer DB 1998 Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by Helicobacter hepaticus.
Helicobacter 3: 69-78.
-
Fonager K, Sorensen HT, Mellemkjaer L, Olsen JH, Olsen J 1998 Risk of colorectal cancer in relatives of patients with inflammatory bowel disease (Denmark).
Cancer Causes Control 9: 389-392.
*
-
Forgue-Lafitte ME, Fabiani B, Levy PP, Maurin N, Flejou JF, Bara J 2007 Abnormal expression of M1/MUC5AC mucin in distal colon of patients with diverticulitis, ulcerative colitis and cancer.
Int. J. Cancer 121: 1543-1549.
*
-
Fosslien E 2000 Molecular pathology of cyclooxygenase-2 in neoplasia.
Ann. Clin. Lab. Sci. 30: 3-21.
-
Fox J 1998 Enterohepatic Helicobacters: natural and experimental models.
Ital. J. Gastroenterol. Hepatol. 30 Suppl. 3: S264-S269.
-
Fox JG, Dewhirst FE, Shen Z, Feng Y, Taylor NS, Paster BJ, Ericson RL, Lau CN, Correa P, Araya JC, Roa I 1998 Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis.
Gastroenterology 114: 755-763.
*
-
Franco J, Saeian K 1999 Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis.
Curr. Gastroenterol. Rep. 1: 95-101.
-
Francois F, Park J, Bini EJ 2006 Colon pathology detected after a positive screening flexible sigmoidoscopy: a prospective study in an ethnically diverse cohort.
Am. J. Gastroenterol. 101: 823-830.
*
-
Frank A, Seitz HK, Bartsch H, Frank N, Nair J 2004 Immunohistochemical detection of 1,N6-ethenodeoxadenosine in nuclei of human liver affected by diseases predisposing to hepato-carcinogenesis.
Carcinogenesis 25: 1027-1031.
*
-
Fredriksson H, Ikonen T, Autio V, Matikainen MP, Helin HJ, Tammela TL, Koivisto PA, Schleutker J 2006 Identification of germline MLH1 alterations in familial prostate cancer.
Eur. J. Cancer 42: 2802-2806.
*
-
Freeman HJ 2008 Colorectal cancer risk in Crohn's disease.
World J. Gastroenterol. 14: 1810-1811.
*
-
Freeman HJ 2001 Colorectal cancer complicating Crohn's disease.
Can. J. Gastroenterol. 15: 231-236.
-
Freeman HJ 2004 Long-term prognosis of early-onset Crohn's disease diagnosed in childhood or adolescence.
Can. J. Gastroenterol. 18: 661-665.
-
Freeman HJ 2008 Natural history and long-term clinical behavior of segmental colitis associated with diverticulosis (SCAD syndrome).
Dig. Dis. Sci. 53: 2452-2457.
*
-
Friedman S, Rubin PH, Bodian C, Harpaz N, Present DH 2008 Screening and surveillance colonoscopy in chronic Crohn's colitis: results of a surveillance program spanning 25 years.
Clin. Gastroenterol. Hepatol. Jun 26 [Epub ahead of print].
-
Fu K, Igarashi S, Jindo O, Ishikawa T, Hirabayashi K, Kotake K, Matsui T, Azuma H, Kaji Y 2008 Synchronous colitic cancers and microcarcinoids in a patient with long-standing and extensive ulcerative colitis: a case report and review of the literature.
Surg. Laparosc. Endosc. Percutan. Tech. 18: 304-307.
-
Fujii S, Ito K, Ito Y, Ochiai A 2008 Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
J. Biol. Chem. 283: 17324-17332.
*
-
Fujita H, Eishi Y, Ishige I, Saitoh K, Takizawa T, Arima T, Koike M 2002 Quantitative analysis of bacterial DNA from Mycobacteria spp., Bacteroides vulgatus, and Escherichia coli in tissue samples from patients with inflammatory bowel diseases.
J. Gastroenterol. 37: 509-516.
*
-
Fujiwara I, Yashiro M, Kubo N, Maeda K, Hirakawa K 2008 Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway.
Dis. Colon Rectum 51: 1387-1394.
*
-
Fukata M, Abreu MT 2007 TLR4 signalling in the intestine in health and disease.
Biochem. Soc. Trans. 35: 1473-1478.
*
-
Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Abreu MT 2007 Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors.
Gastroenterology 133: 1869-1881.
*
-
Fukui K, Hada T, Imanishi H, Liu W, Iwasaki A, Hirano K, Higashino K 1997 The tumor-derived fetal-intestinal alkaline phosphatase cDNA is identical in sequence to the adult intestinal alkaline phosphatase isozyme gene.
Clin. Chim. Acta 265: 57-63.
*
-
Furth EE, Li J, Purev E, Solomon AC, Rogler G, Mick R, Putt M, Zhang T, Somasundaram R, Swoboda R, Herlyn D 2006 Serum antibodies to EpCAM in healthy donors but not ulcerative colitis patients.
Cancer Immunol. Immunother. 55: 528-537.
*
-
Gaertner WB, Hagerman GF, Finne CO, Alavi K, Jessurun J, Rothenberger DA, Madoff RD 2008 Fistula-associated anal adenocarcinoma: good results with aggressive therapy.
Dis. Colon Rectum 51: 1061-1067.
*
-
Galamb O 2008 mRNA expression analysis and classification of colonic biopsy samples using oligonucleotide and cDNA microarray techniques.
Orv. Hetil. 149: 1373-1377.
-
Galamb O, Gyorffy B, Sipos F, Spisak S, Nemeth AM, Miheller P, Dinya E, Molnar B, Tulassay Z 2007 Identification of colorectal cancer, adenoma, and inflammatory bowel disease specific gene expression patterns using whole genomic oligonucleotide microarray system.
Orv. Hetil. 148: 2067-2079.
-
Galvez-Hernandez C, Franklin ME, Villegas-Cabello O, Diaz-Elizondo J, Trevino JM, Salazar-Lopez D 2007 Laparoscopic subtotal colectomy. Results from the Texas Endosurgery Institute.
Cir. Cir. 75: 443-448.
-
Garay CA, Engstrom PF 1999 Chemoprevention of colorectal cancer: dietary and pharmacologic approaches.
Oncology (Huntingt.) 13: 89-97.
-
Garcia Sanchez MV, Gonzalez R, Iglesias Flores E, Gomez Camacho F, Casais Juanena L, Cerezo Ruiz A, Montero Perez-Barquero M, Muntane J, De Dios Vega JF 2006 Diagnostic value of fecal calprotectin in predicting an abnormal colonoscopy.
Med. Clin. (Barc.) 127: 41-46.
-
Garza Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, Flores-Gutierrez JP, Maldonado-Garza HJ, Perez-Perez GI 2007 Assessment of the Toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8 -251 polymorphisms in the risk for the development of distal gastric cancer.
BMC Cancer 7: 70.
*
-
Gatof D, Ahnen D 2002 Primary prevention of colorectal cancer: diet and drugs.
Gastroenterol. Clin. North Am. 31: 587-623, xi.
-
Gearry RB, Wakeman CJ, Barclay ML, Chapman BA, Collett JA, Burt MJ, Frizelle FA 2004 Surveillance for dysplasia in patients with inflammatory bowel disease: a national survey of colonoscopic practice in new zealand.
Dis. Colon Rectum 47: 314-322.
*
-
Gerner EW, Ignatenko NA, Besselsen DG 2003 Preclinical models for chemoprevention of colon cancer.
Recent Results Cancer Res. 163: 58-71.
-
Gibson PR, Jewell DP 1986 Local immune mechanisms in inflammatory bowel disease and colorectal carcinoma. Natural killer cells and their activity.
Gastroenterology 90: 12-19.
-
Gilad LA, Tirosh O, Schwartz B 2006 Phytoestrogens regulate transcription and translation of vitamin D receptor in colon cancer cells.
J. Endocrinol. 191: 387-398.
*
-
Gill S, Blackstock AW, Goldberg RM 2007 Colorectal cancer.
Mayo Clin. Proc. 82: 114-129.
*
-
Gillen CD, Andrews HA, Prior P, Allan RN 1994 Crohn's disease and colorectal cancer.
Gut 35: 651-655.
*
-
Ginsburg PM, Thuluvath PJ 2005 Diarrhea in liver transplant recipients: etiology and management.
Liver Transpl. 11: 881-890.
*
-
Ginty F, Adak S, Can A, Gerdes M, Larsen M, Cline H, Filkins R, Pang Z, Li Q, Montalto MC 2008 The relative distribution of membranous and cytoplasmic Met is a prognostic indicator in stage I and II colon cancer.
Clin. Cancer Res. 14: 3814-3822.
-
Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC 1994 Intake of fat, meat, and fiber in relation to risk of colon cancer in men.
Cancer Res. 54: 2390-2397.
*
-
Girard H, Butler LM, Villeneuve L, Millikan RC, Sinha R, Sandler RS, Guillemette C 2008 UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans.
Mutat. Res. 644: 56-63.
-
Glauben R, Batra A, Stroh T, Erben U, Fedke I, Lehr HA, Leoni F, Mascagni P, Dinarello CA, Zeitz M, Siegmund B 2008 Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice.
Gut 57: 613-622.
-
Goel A, Arnold CN, Tassone P, Chang DK, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR 2004 Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers.
Int. J. Cancer 112: 754-759.
*
-
Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR 2003 A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells.
Clin. Cancer Res. 9: 383-390.
*
-
Goel A, Kunnumakkara AB, Aggarwal BB 2008 Curcumin as "curecumin": from kitchen to clinic.
Biochem. Pharmacol. 75: 787-809.
*
-
Goetz M, Kiesslich R 2008 Confocal endomicroscopy: in vivo diagnosis of neoplastic lesions of the gastrointestinal tract.
Anticancer Res. 28: 353-360.
-
Goh KL, Quek KF, Yeo GT, Hilmi IN, Lee CK, Hasnida N, Aznan M, Kwan KL, Ong KT 2005 Colorectal cancer in Asians: a demographic and anatomic survey in Malaysian patients undergoing colonoscopy.
Aliment. Pharmacol. Ther. 22: 859-864 ..
*
-
Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Collier J 2008 Liver cirrhosis, other liver diseases, pancreatitis and subsequent cancer: record linkage study.
Eur. J. Gastroenterol. Hepatol. 20: 384-392.
-
Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Jewell D 2008 Cancer in patients with ulcerative colitis, Crohn's disease and coeliac disease: record linkage study.
Eur. J. Gastroenterol. Hepatol. 20: 297-304.
-
Goldbohm RA, van den Brandt PA, van 't Veer P, Brants HA, Dorant E, Sturmans F, Hermus RJ 1994 A prospective cohort study on the relation between meat consumption and the risk of colon cancer.
Cancer Res. 54: 718-723.
*
-
Goldin BR, Gorbach SL 2008 Clinical indications for probiotics: an overview.
Clin. Infect. Dis. 46 Suppl. 2: S96-S100.
-
Goldstein ES, Rubin PH 2003 Endoscopic therapy for inflammatory bowel disease.
Curr. Treat. Options Gastroenterol. 6: 237-243.
-
Gommeaux J, Cano C, Garcia S, Gironella M, Pietri S, Culcasi M, Pebusque MJ, Malissen B, Dusetti N, Iovanna J, Carrier A 2007 Colitis and colitis-associated cancer are exacerbated in mice deficient for the tumor protein 53-induced nuclear protein 1.
Mol. Cell. Biol. 27: 2215-2228.
*
-
Gong H, Singh SV, Singh SP, Mu Y, Lee JH, Saini SP, Toma D, Ren S, Kagan VE, Day BW, Zimniak P, Xie W 2006 Orphan nuclear receptor pregnane X receptor sensitizes oxidative stress responses in transgenic mice and cancerous cells.
Mol. Endocrinol. 20: 279-290.
*
-
Gong Z, Xie D, Deng Z, Bostick RM, Muga SJ, Hurley TG, Hebert JR 2005 The PPARgamma Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas.
Carcinogenesis 26: 579-585.
*
-
Gonvers JJ, Harris JK, Wietlisbach V, Burnand B, Vader JP, Froehlich F; EPAGE Study Group 2007 A European view of diagnostic yield and appropriateness of c
| |
